Neurobiological Technologies (Neurobiological Technologies) EBIT : $11.49 Mil (TTM As of Sep. 2009)

View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies EBIT?

Neurobiological Technologies's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2009 was $5.15 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2009 was $11.49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neurobiological Technologies's annualized ROC % for the quarter that ended in Sep. 2009 was 1,312.04%. Neurobiological Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2009 was 1,550.60%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Neurobiological Technologies EBIT Historical Data

The historical data trend for Neurobiological Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies EBIT Chart

Neurobiological Technologies Annual Data

Trend

Jun00

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

EBIT

Get a 7-Day Free Trial

-12.58

-16.44

-15.60

-16.70

3.12

Neurobiological Technologies Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
EBIT	Get a 7-Day Free Trial															-3.22	-8.10	-0.28	14.73	5.15

Competitive Comparison of Neurobiological Technologies's EBIT

For the Biotechnology subindustry, Neurobiological Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurobiological Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's EV-to-EBIT falls into.

Neurobiological Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.49 Mil.

Neurobiological Technologies (OTCPK:NTII) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neurobiological Technologies's annualized ROC % for the quarter that ended in Sep. 2009 is calculated as:

	ROC % (Q: Sep. 2009 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2009 )	+	Invested Capital (Q: Sep. 2009 ))	/ count )
=	20.592 * ( 1 - 1.75% )	/	( (0.417	+	2.667)	/ 2 )
=	20.23164	/	1.542
=	1,312.04 %

where

	Invested Capital		(Q: Jun. 2009 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	24.66	-	0.82	-	( 24.049	-	max(0, 1.115	-	24.538	+	24.049	))
=	0.417

	Invested Capital		(Q: Sep. 2009 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29.782	-	0.626	-	( 26.489	-	max(0, 0.655	-	29.694	+	26.489	))
=	2.667

Note: The Operating Income data used here is four times the quarterly (Sep. 2009) data.

2. Joel Greenblatt's definition of Return on Capital:

Neurobiological Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2009 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2009 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2009		Q: Sep. 2009
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	20.592	/	( ( (0.07 + max(-0.626, 0))	+	(0.036 + max(2.55, 0)) )	/	2 )
=	20.592	/	( ( 0.07	+	2.586 )	/	2 )
=	20.592	/	1.328
=	1,550.60 %

where Working Capital is:

	Working Capital		(Q: Jun. 2009 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.184	+	0	+	0.305)	-	(0.82	+	0	+	0.295)
=	-0.626

	Working Capital		(Q: Sep. 2009 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3	+	0	+	0.205)	-	(0.626	+	0	+	0.029)
=	2.55

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2009) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Neurobiological Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2009 )
	=	11.489	/	0.000
	=	%

Neurobiological Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurobiological Technologies (Neurobiological Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583

Website

http://www.ntii.com

Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Executives

Ariel Warszawski	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp	10 percent owner	426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp	10 percent owner	FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin	director
Abraham E Cohen	director	500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer	director	HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc	other: Direct Beneficial Owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines

From GuruFocus

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-12-2010

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 02-12-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 05-09-2009